ENDRA Life Sciences (NASDAQ:NDRA) Announces Quarterly Earnings Results

ENDRA Life Sciences (NASDAQ:NDRA) issued its quarterly earnings data on Friday. The company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.14, FiscalAI reports.

ENDRA Life Sciences Trading Down 12.0%

NDRA stock opened at $5.05 on Friday. The firm has a 50 day simple moving average of $4.57 and a 200-day simple moving average of $4.74. ENDRA Life Sciences has a twelve month low of $2.91 and a twelve month high of $11.96. The company has a market capitalization of $6.27 million, a P/E ratio of -0.57 and a beta of -0.11.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, ENDRA Life Sciences presently has a consensus rating of “Hold” and a consensus price target of $30.00.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.